Moderna takes over $1 billion in deposits for coronavirus vaccine

30 October 2020
moderna_therapeutics_large

Stock in US biotech Moderna (Nasdaq: MRNA) ended the day up nearly 8.5% on Thursday, following a business update in which the firm said it was “actively preparing” for the launch of its COVID-19 vaccine.

Moderna is developing a novel mRNA-based vaccine which, if approved, would enable a relatively rapid deployment of finished product to customers around the world.

The firm said it had received $1.1 billion of customer deposits for supply of mRNA-1273 in the third quarter of 2020 - money which has been booked as deferred revenue.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology